文献速递类风湿关节炎

活动性类风湿关节炎患者起始或更换改善病情抗风湿药后患者报告结局测量信息系统指标的反应性

Responsiveness of Patient-Reported Outcomes Measurement Information System Measures in Rheumatoid Arthritis Patients Starting or Switching a Disease-Modifying Antirheumatic Drug.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2019-01-01

本研究在正在进行的观察性研究中,对起始改善病情抗风湿药(DMARD)的活动性类风湿关节炎(RA)患者完成8项患者报告结局测量信息系统(PROMIS)指标评估,基线156例平均CDAI为25.5±14.0,12周时106例所有PROMIS评分均改善(P≤0.05),除抑郁外各PROMIS变化与CDAI变化相关(标准化β绝对值0.23至0.38)。

要点

  • 基线时身体健康、疼痛和睡眠的PROMIS评分与基线CDAI评分相关(P≤0.05)。
  • 106例有12周数据的患者中,所有PROMIS评分在起始DMARD后均改善(P≤0.05)。
  • 除抑郁外,所有评估的PROMIS指标变化与CDAI变化相关(标准化β绝对值0.23至0.38)。

核心结论

  • 这些数据支持PROMIS指标用于评估活动性RA患者的躯体和心理健康。
  • 所有PROMIS指标在起始DMARD后均显著改善,PROMIS指标变化与CDAI变化之间的关联强度处于低至中等范围。

研究设计与样本

  • 正在进行的观察性研究,参与者在起始DMARD前后完成8项PROMIS指标。
  • 采用线性回归模型识别基线PROMIS指标与使用临床疾病活动指数(CDAI)测量的疾病活动之间的横断面关联。
  • 采用配对t检验评估DMARD治疗12周后的反应性。
  • 采用线性回归评估PROMIS指标变化与CDAI评分变化之间的关联。
  • 完成首次研究访视的参与者共156例。

主要发现

  • 156例参与者的基线CDAI平均±标准差为25.5±14.0。
  • 基线时身体健康、疼痛和睡眠的PROMIS评分与基线CDAI评分相关(P≤0.05)。
  • 106例有12周数据的参与者中,所有PROMIS评分在起始DMARD后均改善(P≤0.05)。
  • 除抑郁外,所有评估的PROMIS指标变化与CDAI评分变化相关(标准化β绝对值0.23至0.38)。

关键数值与推荐

  • 基线CDAI平均±标准差为25.5±14.0(156例完成首次研究访视的参与者)。
  • 基线时身体健康、疼痛和睡眠的PROMIS评分与基线CDAI评分相关(P≤0.05)。
  • 106例有12周数据的参与者中,所有PROMIS评分在起始DMARD后均改善(P≤0.05)。
  • 除抑郁外,所有评估的PROMIS指标变化与CDAI评分变化相关(标准化β绝对值0.23至0.38)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The Patient-Reported Outcomes Measurement Information System (PROMIS) is a calibrated item bank used to assess patient-reported outcomes across multiple domains. The purpose of this study was to describe the performance of selected PROMIS measures in patients with rheumatoid arthritis (RA) with active disease who were initiating a disease-modifying antirheumatic drug (DMARD). METHODS: Participants in an ongoing prospective observational study completed 8 PROMIS measures before and after DMARD initiation. Linear regression models were performed to identify cross-sectional associations between baseline PROMIS measures and disease activity, measured using the Clinical Disease Activity Index (CDAI). Paired t-tests were performed to evaluate responsiveness after 12 weeks of DMARD treatment. Associations between changes in PROMIS measures and changes in the CDAI score were assessed using linear regression. RESULTS: Among the 156 participants who completed the first study visit, the mean ± SD baseline CDAI score was 25.5 ± 14.0. Baseline scores for PROMIS measures of physical health, pain, and sleep were associated with the baseline CDAI score (P ≤ 0.05). Among the 106 participants with 12-week data, all PROMIS scores improved after DMARD initiation (P ≤ 0.05). With the exception of depression, changes in all assessed PROMIS measures were correlated with changes in the CDAI score (standardized βs from |0.23| to |0.38|). CONCLUSION: These data provide support for the utility of PROMIS measures for the assessment of physical and mental health in individuals with active RA. All PROMIS measures improved significantly after DMARD initiation, with the magnitudes of association between changes in PROMIS measures and changes in the CDAI score in the low-to-moderate range.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Wohlfahrt A, Bingham CO, Marder W, et al. Responsiveness of Patient-Reported Outcomes Measurement Information System Measures in Rheumatoid Arthritis Patients Starting or Switching a Disease-Modifying Antirheumatic Drug. Arthritis Care Res (Hoboken). 2019. PMID: 29885039. doi:10.1002/acr.23617

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。